Fangzhou Inc. Achieves Strong Financial Performance
Fangzhou Inc. (06086.HK), an industry leader in AI-driven Internet healthcare solutions, has unveiled substantial growth in its financial performance for the first half of 2025. This surge is attributed to its expanding network of users and healthcare providers, combined with improved operational efficiencies and accelerated adoption of artificial intelligence across its services.
Key Financial Highlights
Fangzhou demonstrated a remarkable revenue figure of RMB 1.494 billion, marking a 12.9% increase compared to the previous year. In a noteworthy turnaround, the company reported a net profit of RMB 12.5 million, a significant improvement from a loss of RMB 818.7 million during the same timeframe last year. Furthermore, adjusted net profit was also on the rise, climbing 16.8% to reach a milestone of RMB 17.6 million.
User Growth and Engagement
The platform has witnessed impressive user growth, with registered users reaching 52.8 million—up 15.8% year-on-year. Monthly active users surged by 34.4%, totaling 11.9 million. This increase highlights the effectiveness of Jongzhou’s strategies to retain users, including a high paid user repurchase rate of 85.4%, indicating strong customer loyalty.
Revenue Streams and Product Offerings
Fangzhou's financial achievements were bolstered by its online retail pharmacy services, which posted a growth of 28.2%, translating to RMB 864 million. Meanwhile, revenue from medical services rose by 11.4%, reaching RMB 357 million. By the mid-point of 2025, Fangzhou's drug catalog expanded to include 215,000 stock-keeping units (SKUs), with approximately 62% consisting of prescription medications, facilitated through robust partnerships with over 1,650 suppliers and 980 pharmaceutical companies.
Innovations in Drug Launches
The company has strategically collaborated with leading pharmaceutical firms to introduce a range of innovative drugs on its platform, including partnerships with industry giants such as Novo Nordisk, Otsuka Pharmaceutical, Novartis AG, and Takeda Pharmaceuticals.
Future-Driven Initiatives
Company founder and CEO, Dr. Xie Fangmin, expressed optimism about Fangzhou’s strategic direction. He stated, "Our strong half-year results reflect both the resilience of our business model and the accelerating value of implementing AI in chronic disease management. By upgrading the full patient journey and deepening collaboration with global and local partners, we are well positioned to deliver sustained growth while contributing to our broader health objectives.”
AI-Driven Health Management
Fangzhou continues to leverage AI across its operations, improving areas such as procurement, marketing, content creation, and user services. The upgraded "AI+H2H" platform is designed to enhance health consultations and manage chronic diseases effectively. The company’s AI diagnostic tool provides around-the-clock support, assisting doctors in compiling patients’ symptoms and medical histories.
Enhanced User Support Systems
To ensure patients receive optimal care, AI-driven customer service tools facilitate medication adherence, thereby minimizing operational costs while ensuring quality health outcomes.
Strengthening National Healthcare Integration
Fangzhou's efforts to integrate with the national medical insurance system have gained traction, following the successful introduction of online consultation and prescription services last year. These enhancements are designed to improve connectivity and expand service capabilities, setting the stage for future regional growth.
Vision for Digital Healthcare
As it looks ahead, Fangzhou plans to adopt a strategy centered on technological innovation and digital integration. By further embedding AI into their operations, the company aims to foster applications in chronic disease management. It will also pursue collaborations with both global and domestic pharmaceutical companies, health institutions, and insurers to create a diverse digital healthcare ecosystem.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) stands out as a premier platform for chronic disease management, currently serving 52.8 million registered users and 229,000 medical professionals. The firm excels in providing personalized medical care and precision medicine solutions tailored to individual needs.
Contact Information
For media inquiries or further information, please reach out to:
Xingwei Zhao, Associate Director of Public Relations. You can contact through email at pr@jianke.com.
Frequently Asked Questions
What key financial metrics did Fangzhou report for 1H 2025?
Fangzhou reported a revenue of RMB 1.494 billion and a net profit of RMB 12.5 million for the first half of 2025.
How many registered users are currently on Fangzhou's platform?
As of the latest report, there are 52.8 million registered users on Fangzhou's platform.
What innovations has Fangzhou introduced this year?
Fangzhou has launched innovative drugs in collaboration with major pharmaceutical companies and enhanced its AI capabilities across various services.
How does Fangzhou enhance patient care?
The company utilizes advanced AI tools to support real-time health consultations and long-term disease management, improving patient and doctor interactions.
What are Fangzhou's future plans?
Fangzhou plans to further integrate technology in its operations and expand collaborations with various stakeholders in the healthcare sector.
